430 related articles for article (PubMed ID: 29224199)
1. Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients.
Peer FC; Miller A; Pavli P; Subramaniam K
Intern Med J; 2017 Dec; 47(12):1445-1448. PubMed ID: 29224199
[TBL] [Abstract][Full Text] [Related]
2. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
Bae JM; Lee HH; Lee BI; Lee KM; Eun SH; Cho ML; Kim JS; Park JM; Cho YS; Lee IS; Kim SW; Choi H; Choi MG
Aliment Pharmacol Ther; 2018 Jul; 48(2):196-205. PubMed ID: 29869804
[TBL] [Abstract][Full Text] [Related]
3. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
[TBL] [Abstract][Full Text] [Related]
4. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
[TBL] [Abstract][Full Text] [Related]
5. Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease.
George LA; Gadani A; Cross RK; Jambaulikar G; Ghazi LJ
Dig Dis Sci; 2015 Nov; 60(11):3424-30. PubMed ID: 26115749
[TBL] [Abstract][Full Text] [Related]
6. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L
Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease.
Buisson A; Cuny JF; Barbaud A; Schmutz JL; Bigard MA; Guéant JL; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2012 May; 35(10):1175-80. PubMed ID: 22469155
[TBL] [Abstract][Full Text] [Related]
8. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.
Cullen G; Kroshinsky D; Cheifetz AS; Korzenik JR
Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1318-27. PubMed ID: 21957906
[TBL] [Abstract][Full Text] [Related]
9. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.
Guerra I; Algaba A; Pérez-Calle JL; Chaparro M; Marín-Jiménez I; García-Castellanos R; González-Lama Y; López-Sanromán A; Manceñido N; Martínez-Montiel P; Quintanilla E; Taxonera C; Villafruela M; Romero-Maté A; López-Serrano P; Gisbert JP; Bermejo F
J Crohns Colitis; 2012 Jun; 6(5):518-23. PubMed ID: 22398059
[TBL] [Abstract][Full Text] [Related]
10. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
[TBL] [Abstract][Full Text] [Related]
11. Anti-Tumor Necrosis Factor-α-Induced Dermatological Complications in a Large Cohort of Inflammatory Bowel Disease Patients.
Andrade P; Lopes S; Gaspar R; Nunes A; Magina S; Macedo G
Dig Dis Sci; 2018 Mar; 63(3):746-754. PubMed ID: 29349693
[TBL] [Abstract][Full Text] [Related]
12. Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review.
Melo FJ; Magina S
Int J Dermatol; 2018 Dec; 57(12):1521-1532. PubMed ID: 30028008
[TBL] [Abstract][Full Text] [Related]
13. Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis.
Xie W; Xiao S; Huang H; Zhang Z
Front Immunol; 2022; 13():847160. PubMed ID: 35300336
[TBL] [Abstract][Full Text] [Related]
14. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study.
Pugliese D; Guidi L; Ferraro PM; Marzo M; Felice C; Celleno L; Landi R; Andrisani G; Pizzolante F; De Vitis I; Papa A; Rapaccini GL; Armuzzi A
Aliment Pharmacol Ther; 2015 Oct; 42(7):880-8. PubMed ID: 26235565
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G
Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839
[TBL] [Abstract][Full Text] [Related]
16. Paradoxical Psoriasiform Eruptions in Children Receiving Tumor Necrosis Factor α Inhibitors.
Eickstaedt J; Paller AS; Lund E; Murphrey M; Brandling-Bennett H; Maurano M; Fernandez Faith E; Holland KE; Ibler E; Liang MG; Todd PS; Siegfried E; Igelman S; Cordoro KM; Tollefson MM
JAMA Dermatol; 2023 Jun; 159(6):637-642. PubMed ID: 37043214
[TBL] [Abstract][Full Text] [Related]
17. Psoriasiform reactions to anti-tumor necrosis factor α therapy.
Nguyen K; Vleugels RA; Velez NF; Merola JF; Qureshi AA
J Clin Rheumatol; 2013 Oct; 19(7):377-81. PubMed ID: 24048106
[TBL] [Abstract][Full Text] [Related]
18. Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy.
Nigam GB; Bhandare AP; Antoniou GA; Limdi JK
Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):346-357. PubMed ID: 32889976
[TBL] [Abstract][Full Text] [Related]
19. [Paradoxical psoriasis induced by anti-TNF - a clinical challenge].
Nidegger A; Mylonas A; Conrad C
Rev Med Suisse; 2019 Mar; 15(644):668-671. PubMed ID: 30916904
[TBL] [Abstract][Full Text] [Related]
20. Dermatological Manifestations in Pediatric Patients with Inflammatory Bowel Diseases on Anti-TNF Therapy.
Sridhar S; Maltz RM; Boyle B; Kim SC
Inflamm Bowel Dis; 2018 Aug; 24(9):2086-2092. PubMed ID: 29718343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]